

Historical Perspectives of Glucagon's Discovery and Early Research

Debashish Brahmachari, Shabeen Naz Masood¹, Umaira Aziz², Tatjana Milenkovic³, Manoj Chawla⁴, A. G. Unnikrishnan⁵, Sujoy Ghosh⁶, João Raposo⁷, Banshi Saboo⁸, Viswanathan Mohan⁹

Department of Medical Sciences, Scientific Publishing Group, New Delhi, India, ¹Department of Obstetrics and Gynecology, Isra University, Karachi, Pakistan, ²Emirates Health Services, Ibrahim bin Hamad Obaidullah Hospital, Ras Al-Khaimah, UAE, ³Department of Endocrinology, Diabetes and Metabolic Disorders, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, Skopje, Republic of North Macedonia, ⁴Department of Diabetology, P.D. Hinduja Hospital and Medical Research Centre, Mumbai, Maharashtra, India, ⁵Chellaram Diabetes Institute, Pune, Maharashtra, India, ⁶Department of Endocrinology, Institute of Postgraduate Medical Education & Research, Kolkata, West Bengal, India, ⁷Nova Medical School, New University of Lisbon, Lisbon, Portugal, ⁸Department of Diabetology, Diabetes Care & Hormone Clinic, Ahmedabad, Gujarat, India, ⁹Department of Diabetology, Madras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialties Centre, Chennai, Tamil Nadu, India

Abstract

This review article looks at the historical journey of the discovery of glucagon and the initial stages of research that paved the way for a comprehensive understanding of its physiological significance. Glucagon, an essential peptide hormone produced by the pancreas, plays a pivotal role in maintaining glucose homeostasis. Tracing the trajectory of its discovery from its initial identification to the unraveling of its complex functions, this article offers a detailed analysis of the early scientific endeavors, and collaborations that contributed to shaping our understanding of glucagon's pivotal role. By exploring the historical context, controversies, and advancements, this review sheds light on the evolution of endocrinological knowledge and its profound implications for diabetes research and treatment strategies.

Keywords: Diabetes, endocrinology, glucagon, glucose homeostasis, historical research, hormone discovery, insulin, pancreatic hormones, therapeutic applications

INTRODUCTION

Glucagon, an enigmatic subject of study, embarked on a journey marked by serendipity and scientific intrigue. It is interesting that Glucagon was actually identified from early insulin preparations as an impurity that caused, causing a surge in blood glucose levels and even increased mortality.^[1,2] Kimball and Murlin christened the hormone as Glucagon (GLUCose-AGONist), embodying its capacity to elevate glucose levels in depancreatized dogs. But it took a quarter of a century before Sutherland and De Duve succeeded in purifying the elusive hormone.^[3]

Glucagon is a 29-amino acid linear peptide hormone and it is emerged as a crucial regulator in the intricate balance of metabolic equilibrium. Principally secreted by

the pancreatic α cells, it shares an ancestral lineage with GLP-1 and GLP-2, owing to their common precursor, proglucagon. This intriguing molecular relationship fuels the orchestration of metabolic processes that reverberate across multiple organ systems.

These peptides share substantial sequence similarity, collectively constituting the glucagon family—a distinctive subset within the secretin-glucagon superfamily. Amidst this familial framework, the foundational structure of glucagon is best known in vertebrates. Manifesting its

Address for correspondence: Dr. Viswanathan Mohan, Madras Diabetes Research Foundation, ICMR Centre for Advanced Research on Diabetes & Dr. Mohan's Diabetes Specialties Centre, IDF Centre of Excellence in Diabetes Care, No 4, Conran Smith Road, Gopalapuram, Chennai 600 086, Tamil Nadu, India. E-mail: drmohans@diabetes.ind.in

Received: 16-October-2023, Revised: 30-October-2023, Accepted: 16-October-2023, Published: 14-November-2023

Access this article online

Quick Response Code:



Website:
<https://journals.lww.com/JODB>

DOI:
10.4103/jod.jod_107_23

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow_reprints@wolterskluwer.com

How to cite this article: Brahmachari D, Masood SN, Aziz U, Milenkovic T, Chawla M, Unnikrishnan AG, *et al.* Historical perspectives of glucagon's discovery and early research. J Diabetol 2023;14:S8-10.

role as the principal hyperglycemic hormone, glucagon orchestrates a delicate equilibrium alongside insulin. Its action includes the promotion of gluconeogenesis and glycogenolysis, leading to elevation in blood glucose levels. While its impact is most marked within the liver, the influence of glucagon extends to various bodily organs, including adipose tissue, pancreas, brain, and kidney.^[4]

GLUCAGON'S UNVEILING: PIONEERS OF DISCOVERY

The trajectory of glucagon research spans across several decades, tracing its roots back to a pivotal moment in medical history. In 1921, the discovery of insulin by Banting and Best came with an intriguing observation—pancreatic extracts wielded not just one, but a duality of hyperglycemic and hypoglycemic properties.^[5]

Two years later, Murlin *et al.*^[6] carved a distinct identity for one of these properties. Isolating a pancreatic extract with hyperglycemic activity, they christened this entity “glucagon” (GLUCose-AGONist). This naming marked the inception of an endeavor that would unravel the intricate workings of a powerful hormone.

The year 1948 saw a monumental breakthrough. Sutherland and de Duve's efforts culminated in the isolation of glucagon within the pancreatic α -cells, providing a new layer of understanding to its intricate localization.^[7] This milestone paved the way for deeper exploration, fueled by the establishment of the amino acid sequence of glucagon in 1956 by Bromer *et al.*^[8]

The year 1959 ushered in yet another critical development—the inception of a radioimmunoassay for glucagon by Unger *et al.*^[9] This innovation breathed life into quantification, enabling researchers to measure and comprehend the hormone's dynamic presence.

Glucagon, then became a subject of intense scrutiny. An ensemble of animal models—from mice and rats to dogs, pigs, and nonhuman primates—were studied in scientific research on the hormone. This led to outcomes across myriad animal models while the findings in humans accentuated the profound translational value of investigating glucagon's role in physiology.

Thus, the tale of glucagon research navigates a historical tapestry, embellished with key discoveries and innovations. A testament to the enduring intrigue of hormonal orchestration, this research journey underscores the profound impact of glucagon in the intricate narrative of human health.

GUARDIAN OF GLUCOSE EQUILIBRIUM: DISCOVERY OF GLUCAGON'S ESSENTIAL ROLE

Embedded within the pancreatic islets, the A-cells, also known as α (alpha)-cells, give rise to a pivotal polypeptide

hormone known as glucagon. This hormone's primary risk is in preventing a perilous plunge in blood glucose levels, thus safeguarding the delicate equilibrium that fuels our physiological processes.^[10] Unlocking its therapeutic potential, glucagon emerges as an integral player, initially derived from the pancreases of bovines or pigs, and later synthesized through the alchemy of recombinant DNA.

Glucagon is secreted in response to hypoglycemia and its response is regulated by both endocrine and autonomic pathways.^[10]

Glucagon also combines with adenylate cyclase leading to surge of glycogenolysis and gluconeogenesis within the hepatocytes.^[11]

Simultaneously, the adipose tissue is activated when lipolysis is also summoned into action.^[12]

The hormone's action extends beyond metabolism as it works on the smooth muscles with a rise in cyclic AMP.^[13]

However, it's in the realm of therapeutic intervention that glucagon's impact truly resonates. In individuals with diabetes managed with insulin, glucagon's role is significant as it is the hormone that protects against hypoglycemia. The reversal of hypoglycemia, a perilous state often challenging diabetic individuals, finds its resolution through glucagon's intervention.

Unger^[14] added further light on glucagon's role in the intricate web of metabolic perturbations. This understanding led to a new horizon—developing antagonists targeting the glucagon receptor.

Amid this canvas, peptidic antagonists like desHis1, desPhe6, and Glu9 glucagon amide step forward, as crafted by Ying *et al.* were of interest.^[15]

However, the spotlight was soon seized by an even more riveting narrative—non-peptidic antagonists described by Madsen *et al.*,^[16] Ladouceur *et al.*, thereby leading to further therapeutic innovation.^[17]

In the ever-evolving tale of glucagon which is not just a hormone but a protagonist—glucagon is a guardian of balance and a beacon of hope for those grappling with the intricacies of diabetes. From its intricate biochemical footwork to its therapeutic potential, glucagon's narrative remains poised to play an increasingly bigger role in the management of diabetes and possibly weight reduction as triple agonist therapy in the form of retatrutide, etc.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Fisher NF. Preparation of insulin. *Am J Physiol* 1923;67:57-64.
2. Collip JB. Delayed manifestation of the physiological effects of insulin following the administration of certain pancreatic extracts. *Am J Physiol* 1923;63:391-2.
3. Sutherland EW, Cori CF, Haynes R, Olsen NS. Purification of the hyperglycemic-glycogenolytic factor from insulin and from gastric mucosa. *J Biol Chem* 1949;180:825-37.
4. Tachibana T. *Handbook of Hormones: Comparative Endocrinology for Basic and Clinical Research*. 2nd ed. Cambridge, MA: Academic Press; 2021: p. 231-4.
5. Banting FG, Best CH. The internal secretion of the pancreas. *J Lab Clin Med* 1921;7:251-66.
6. Kimball C, Murlin J. Aqueous extracts of pancreas III. Some precipitation reactions of insulin. *J Biol Chem* 1923;58:337-48.
7. Sutherland EW, de Duve C. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. *J Biol Chem* 1948;175:663-74.
8. Bromer WW, Winn LM, Behrens OK. The Amino Acid Sequence of Glucagon. *J Biol Chem* 1956;218:331-46.
9. Unger RH, Eisentraut AM, Madison LL. The Effects of Total Starvation upon the Levels of Plasma Glucagon and Insulin in Man. *J Clin Invest* 1959;38:2256-63.
10. Taborsky GJ, Jr, Ahren B, Havel PJ. Autonomic mediation of glucagon secretion during hypoglycemia: Implications for impaired alpha-cell responses in type 1 diabetes. *Diabetes* 1998;47:995-1005.
11. Exton JH. Mechanisms of hormonal regulation of hepatic glucose metabolism. *Diabetes Metab Rev* 1987;3:163-83.
12. Schade DS, Eaton RP, Davis L. Adrenergic mechanisms in the control of lipolysis and thermogenesis. *Metabolism* 1979;28:373-88.
13. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. *Am J Physiol Endocrinol Metab* 2003;284:E671-8.
14. Unger RH. Glucagon and the insulin: Glucagon ratio in diabetes and other catabolic illnesses. *Diabetes* 1978;20:834-8.
15. Ying J, Ahn JM, Jacobsen NE, Brown MF, Hruby VJ. NMR solution structure of the glucagon antagonist [desHis1, desPhe6, Glu9]glucagon amide in the presence of perdeuterated dodecylphosphocholine micelles. *Biochemistry* 2003;42:2825-35.
16. Madsen P, Knudsen LB, Wiberg FC, Carr RD. Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. *J Med Chem* 1998;41:5150-7.
17. Ladouceur GH, Cook JH, Doherty EM, Schoen WR, MacDougall ML, Livingston JN. Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists. *Bioorg Med Chem Lett* 2002;12:461-4.